Hormone replacement therapy and breast density changes

Climacteric

Volumn 8, Issue 2, 2005, Pages 185-192

  Harvey, J ^a,c   Scheurer, C ^b   Kawakami, F T ^b   Quebe Fehling, E ^b   Ibarra De Palacios, P ^b   Ragavan, V V ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Breast density; Estalis; Hormone replacement therapy; Kliogest; Menopause; Transdermal hormone delivery

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE;

ADULT; AGED; AGING; ARTICLE; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTALGIA; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; BREAST; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAMMOGRAPHY; MIDDLE AGED; POSTMENOPAUSE;

EID: 20844432029     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130500103458     Document Type: Article

References (27)

1. Rutter CM, Mandelson MT, Laya MB, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001; 285:171-6
2. McNicholas MMJ, Heneghan JP, Milner MH, Tunney T, Hourihane JB, MacErlaine DP. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. Am J Roentgenol 1994;163:311-15
3. Stomper PC, Van Voorhis BJ, Ravnikar VA, Meyer JE. Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology 1990; 174:487-90
4. Berkowitz JE, Gatewood OMB, Goldblum LE, Gayler BW. Hormonal replacement therapy: mammographic manifestations. Radiology 1990;174:199-201
5. Persson I, Thurfjell E, Holmeberg L. Effect on estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997;15:3201-17
6. Laya MB, Gallagher JC, Schreiman JS, Larson EB, Watson P, Weinstein L. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 1995;196:433-7
7. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999;130:262-9
8. Sendag F, Terek MC, Ozseneeer S, et al. Mammographic density changes during different postmenopausal hormone replacement therapies. Fertil Steril 2001;76: 3:445-50
9. Marsh MS, Whitcroft S. Whitehead MI. Paradoxical effects of hormone replacement therapy on breast tenderness in postmenopausal women. Maturitas 1994;19:97-102
10. Powers MS, Schenkel L, Darley PE, et al. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985;152:1099-106
11. Lippert TH, Seeger H, Mueck AO. Estradiol metabolism during oral and transdermal estradiol replacement therapy in postmenopausal women. Horm Metab Res 1998;30:598-600
12. Byng JW, Yaffe MJ, Jong RA, et al. Analysis of mammographic density and breast cancer risk for digitized mammograms. RadioGraphics 1998;18:1587-98
13. Harvey J, Williams M, Petroni G, Bovberg V. Establishing a scale of clinically meaningful change in breast density in women using hormone replacement therapy using visual and digital assessment. Breast Cancer Res Treat 2002;76:S149
14. Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gyncol 1999;181:348-52
15. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. JAMA 2003;289: 3243-53
16. Harvey JA. Use and cost of breast imaging for postmenopausal women undergoing hormone replacement therapy. Am J Roentgenol 1999; 172:1615-19
17. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-9
18. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91
19. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10: 253-60
20. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32
21. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-33
22. Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000;9:911-15
23. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88
24. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281: 2189-97
25. Freedman M, San Martin J, O'Gorman J, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 2001;93:51-6
26. Speroff L. The Million Women Study and breast cancer. Maturitas 2003;2546:1-6
27. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362: 419-27